- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02783755
A mHealth Behavioral Cancer Pain Protocol for Medically Underserved Communities
August 15, 2019 updated by: Duke University
A mHealth Behavioral Cancer Pain Protocol for Medically Underserved Communities.
The purpose of this study is two-fold.
First, the investigator will develop a low-literacy Mobile Pain Coping Skills Training (mPCST) protocol for cancer patients with pain (i.e., therapist manual, patient manual including handouts, and the smartphone materials) as well as a beta version of the basic smartphone components with the assistance of experts in the field.
Next, an iterative development design using focus groups with women who have breast cancer and pain accrued from medically underserved areas will be used to refine the developed mPCST protocol and basic smart phone components.
The protocol-designed to reduce cancer pain and disability in patients with low literacy in medically underserved areas-will be delivered via tele-video conferencing sessions in the community clinic.
The smartphone tools (e.g., simple text messages, images, and preloaded intervention content) will allow the intervention to extend into the patients' homes.
The second study purpose is to pilot test the feasibility, acceptability, and efficacy of the developed protocol.
The investigator will also obtain an estimate of the effect size of the developed protocol to decrease pain.
Focus group data will be managed and evaluated in a systematic format using a grounded theory approach.
Data analyses for the pilot testing period of the study will be assessed by examining accrual, attrition, and adherence to the intervention.
Simple t-tests will be used to examine pre- to post-intervention differences in pain and the other outcomes of interest.
There are minimal risk or safety issues related to this study.
Study Overview
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- diagnosis of breast cancer within the last three years
- being >21 years old,
- having a life expectancy of at least 12 months,
- having 1 clinical pain ratings of >3 gathered as part of their routine clinic visits
Exclusion Criteria:
- metastases to the brain,
- presence of a severe psychiatric condition (i.e., psychotic disorder or episode) or a psychiatric condition (e.g., suicidal intent) that would contraindicate safe participation in the study as indicated by the medical chart, treating oncologist, or interactions with the medical/study staff,
- current or past (<6 months) engagement in PCST for cancer.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mobile Health Pain Coping Skills Training (mPCST)
Mobile Health Pain Coping Skills Training (mPCST) protocol for breast cancer survivors with persistent pain that will produce significant improvements in pain, pain disability, fatigue, physical disability, and adherence to post-treatment lifestyle recommendations that are impacted by pain (i.e., daily activity, self-monitoring of symptoms).
|
Coping Skills Training for pain will be delivered to participants using video-conferencing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in pain severity will be assessed with the Brief Pain Inventory (BPI).
Time Frame: Baseline and post intervention, approximately 60 minutes
|
Baseline and post intervention, approximately 60 minutes
|
Change in pain Interference will be assessed with the Brief Pain Inventory (BPI)
Time Frame: Baseline and Post Intervention, approximately 60 minutes
|
Baseline and Post Intervention, approximately 60 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in self-efficacy for pain control will be assessed with the self-efficacy for pain management subscale of the Chronic Pain Self-Efficacy Scale.
Time Frame: Baseline and Post Intervention, approximately 60 minutes
|
Baseline and Post Intervention, approximately 60 minutes
|
|
Change in pain catastrophizing will be assessed with the Coping Strategies Questionnaire.
Time Frame: Baseline and Post Intervention, approximately 60 minutes
|
Baseline and Post Intervention, approximately 60 minutes
|
|
Change in Depressive Symptoms:(PROMIS )four-item Depression Scale, a self-report measure of depressive symptoms.
Time Frame: Baseline and Post Intervention, approximately 60 minutes
|
Baseline and Post Intervention, approximately 60 minutes
|
|
Change in fatigue
Time Frame: Baseline and Post Intervention, approximately 60 minutes
|
The Patient Reported Outcomes Measurement Information System (PROMIS) four-item Fatigue Scale is a self-report measure of fatigue symptoms.
|
Baseline and Post Intervention, approximately 60 minutes
|
Change in mPCST Acceptability, as measured by participants' engagement
Time Frame: Sessions 2,3,4 and 5
|
Patient acceptability of mPCST will be assessed with the Client Satisfaction Questionnaire 10-item version that rates items from 1 = low acceptability and 4 = high acceptability
|
Sessions 2,3,4 and 5
|
change in Health-Related Quality of Life
Time Frame: Baseline and Post Intervention, approximately 60 minutes
|
The Functional Assessment of Cancer Therapy- General (FACT-G) will be used to assess participants' health-related quality of life.
The FACT-G is a 7-item self-report measure that provides participants with a variety of symptoms and concerns.
|
Baseline and Post Intervention, approximately 60 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2016
Primary Completion (Actual)
June 1, 2017
Study Completion (Actual)
June 30, 2017
Study Registration Dates
First Submitted
May 24, 2016
First Submitted That Met QC Criteria
May 24, 2016
First Posted (Estimate)
May 26, 2016
Study Record Updates
Last Update Posted (Actual)
August 19, 2019
Last Update Submitted That Met QC Criteria
August 15, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00065621
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
Clinical Trials on Device: smartphone
-
Women's Hospital School Of Medicine Zhejiang UniversityNot yet recruitingDigital Cognitive Behavioral Therapy for Insomnia (dCBT-I)
-
University of California, San FranciscoCompleted
-
University of TorontoHeart and Stroke Foundation of Canada; Dietitians of CanadaCompletedDiet, Food, and Nutrition | Consumer BehaviorCanada
-
Dartmouth-Hitchcock Medical CenterCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
University of ConnecticutNational Heart, Lung, and Blood Institute (NHLBI); Worcester Polytechnic InstituteCompleted
-
Hacettepe UniversityRecruitingPostural; Defect | Dual Task | Smartphone AddictionTurkey
-
University of ManchesterCity, University of London; Schepens Eye Research InstituteTerminated
-
Goethe UniversityKing's College London; Radboud University Medical Center; Heidelberg University; Hospital Vall d'HebronCompletedDepression | Obesity | Attention-Deficit / Hyperactivity DisorderGermany, Netherlands, Spain, United Kingdom
-
University of California, San FranciscoNot yet recruiting
-
University of OklahomaWithdrawnRisk Reduction Behavior